EP2994130A1 - Fgf modulation of in vivo antibody production and humoral immunity - Google Patents
Fgf modulation of in vivo antibody production and humoral immunityInfo
- Publication number
- EP2994130A1 EP2994130A1 EP13884155.6A EP13884155A EP2994130A1 EP 2994130 A1 EP2994130 A1 EP 2994130A1 EP 13884155 A EP13884155 A EP 13884155A EP 2994130 A1 EP2994130 A1 EP 2994130A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mammal
- alpha
- fgf2
- methyl
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000016784 immunoglobulin production Effects 0.000 title claims abstract description 46
- 238000001727 in vivo Methods 0.000 title abstract description 7
- 230000004727 humoral immunity Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 55
- 230000001965 increasing effect Effects 0.000 claims abstract description 20
- 241000124008 Mammalia Species 0.000 claims description 83
- 230000028996 humoral immune response Effects 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000007812 deficiency Effects 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 238000002255 vaccination Methods 0.000 claims description 12
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 10
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 claims description 9
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 9
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 9
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 9
- 229960001131 ponatinib Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- KGWWHPZQLVVAPT-STTJLUEPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C=2C=CC=CC=2)=N1 KGWWHPZQLVVAPT-STTJLUEPSA-N 0.000 claims description 8
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 8
- 229960002412 cediranib Drugs 0.000 claims description 8
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 8
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 claims description 7
- NHFDRBXTEDBWCZ-NTEUORMPSA-N 3-[2,4-dimethyl-5-[(e)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C\2C3=CC=CC=C3NC/2=O)=C1C NHFDRBXTEDBWCZ-NTEUORMPSA-N 0.000 claims description 7
- 229950005778 dovitinib Drugs 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229960004378 nintedanib Drugs 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 claims 6
- 101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 claims 6
- 230000000694 effects Effects 0.000 abstract description 40
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 48
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 48
- 229940126864 fibroblast growth factor Drugs 0.000 description 43
- 239000000427 antigen Substances 0.000 description 37
- 108091007433 antigens Proteins 0.000 description 37
- 102000036639 antigens Human genes 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 230000027455 binding Effects 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 29
- 210000001280 germinal center Anatomy 0.000 description 25
- 210000003719 b-lymphocyte Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 108091008794 FGF receptors Proteins 0.000 description 21
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000003053 immunization Effects 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 238000002649 immunization Methods 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 16
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 14
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 230000009261 transgenic effect Effects 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 230000012178 germinal center formation Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 210000004180 plasmocyte Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 7
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 101150019331 FGF2 gene Proteins 0.000 description 6
- -1 FGFR1 Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 description 5
- 108010046016 Peanut Agglutinin Proteins 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000007813 immunodeficiency Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000019361 Syndecan Human genes 0.000 description 4
- 108050006774 Syndecan Proteins 0.000 description 4
- 102000003705 Syndecan-1 Human genes 0.000 description 4
- 108090000058 Syndecan-1 Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 102000025171 antigen binding proteins Human genes 0.000 description 4
- 108091000831 antigen binding proteins Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 230000003844 B-cell-activation Effects 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 3
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 3
- 208000004518 IgG Deficiency Diseases 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005014 ectopic expression Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Chemical class COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Chemical class CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 2
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 102100039564 Leukosialin Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940097217 cardiac glycoside Drugs 0.000 description 2
- 239000002368 cardiac glycoside Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Chemical class C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 229940124735 malaria vaccine Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 108010055746 trinitrophenyl-bovine serum albumin Proteins 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- BLQYVHBZHAISJM-CMDGGOBGSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(\C=C\C=2C=CC=CC=2)=N1 BLQYVHBZHAISJM-CMDGGOBGSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101100281005 Bos taurus FGF2 gene Proteins 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 229940123256 Fibroblast growth factor antagonist Drugs 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101100281007 Gallus gallus FGF2 gene Proteins 0.000 description 1
- 101100012877 Gallus gallus FGFR1 gene Proteins 0.000 description 1
- 101100012885 Gallus gallus FGFR2 gene Proteins 0.000 description 1
- 101100334736 Gallus gallus FGFR3 gene Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 101000827688 Homo sapiens Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010063743 Hypophagia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100281010 Mus musculus Fgf2 gene Proteins 0.000 description 1
- 101100012881 Mus musculus Fgfr1 gene Proteins 0.000 description 1
- 101100334732 Mus musculus Fgfr2 gene Proteins 0.000 description 1
- 101100334739 Mus musculus Fgfr3 gene Proteins 0.000 description 1
- 101100334745 Mus musculus Fgfr4 gene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- LTEJRLHKIYCEOX-OCCSQVGLSA-N brivanib alaninate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)[C@H](C)N)=C1 LTEJRLHKIYCEOX-OCCSQVGLSA-N 0.000 description 1
- 229950005993 brivanib alaninate Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229950004444 erdafitinib Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000055705 human FGFR1 Human genes 0.000 description 1
- 102000055736 human FGFR2 Human genes 0.000 description 1
- 102000055709 human FGFR3 Human genes 0.000 description 1
- 102000055699 human FGFR4 Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- CPMDPSXJELVGJG-UHFFFAOYSA-N methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound OC=1NC2=CC(=CC=C2C=1C(=NC1=CC=C(C=C1)N(C(CN1CCN(CC1)C)=O)C)C1=CC=CC=C1)C(=O)OC CPMDPSXJELVGJG-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 208000010979 non-small cell squamous lung carcinoma Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000012898 one-sample t-test Methods 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical class O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the field of humoral immunity.
- Organisms control antibody production at multiple steps during an immune response and this response must be carefully adjusted to the invading pathogen. If the response is excessive, autoimmune defects can damage host tissues, whereas if it is inadequate, the pathogen may persist and threaten survival. Soluble factors have been identified that stimulate the humoral immune response, but our knowledge of negative regulators of this process has been quite limited (Ravetch et al, 2000, Science 290:84). Indeed, few soluble cytokines have been identified whose loss of function leads to enhanced antibody production.
- Extrafollicular responses are thought to be important following exposure to T- independent antigens (Fagarasan et al., 2000, Science 290:89; Martin et al., 2001.
- B cells return to a resting state. Turning off B cell activation is necessary both for homeostatic resetting of antibody secretion and also for preventing pathologic autoimmune conditions. Little is known about the soluble factors which control the deactivation process.
- FGF fibroblast growth factor
- FGF2 or basic FGF
- U.S. Patent No. 4,994,559 discloses human basic fibroblast growth factor.
- U.S. Patent No. 5,229,501 discloses expression and use of human fibroblast growth factor receptor.
- U.S. Patent No. 5,228,855 discloses an extracellular form of human fibroblast growth factor receptor.
- U.S. Patent No. 5,707,632 discloses receptors for fibroblast growth factors.
- U.S. Patent No. 5,891,655 discloses methods for identifying molecules that regulate FGF activity and oligosacharide modulators of FGF receptor activation.
- U.S. Patent No. 6,071,885 discloses treatment of FGF-mediated conditions by administration of cardiac glycoside and aglycone derivatives thereof.
- U.S. Patent No. 6,350,593 discloses receptors for fibroblast growth factors and methods for evaluating compositions for antagonism to fibroblast growth factors and fibroblast growth factors receptors.
- U.S. Patent No. 6,255,454 discloses expression and use of a human fibroblast growth receptor and a soluble version of the receptor.
- U.S. Patent No. 6,900,053 discloses antisense modulation of fibroblast growth factor receptor 2 expression.
- FGF fibroblast growth factor
- FGF2 is an inhibitor of the humoral immune response.
- splenic germinal centers require FGF2 for efficient formation.
- One embodiment of the invention provides a method for increasing humoral immune response to vaccination with an immunogen, for example, an antigen or a live or killed vaccine, in a mammal or other higher vertebrate, that includes: in conjunction with the vaccination of a mammal to the immunogen other than FGF2, inhibiting the activity of a fibroblast growth factor, such as FGF2, in the mammal, thereby increasing the humoral immune response to the antigen.
- an immunogen for example, an antigen or a live or killed vaccine
- FGF2 fibroblast growth factor
- the immunogen is other than a fibroblast growth factor and other than a fibroblast growth factor receptor.
- Another embodiment of the invention provides a method for treating an immune deficiency in a mammal, such as a human, that includes: increasing the production of endogenous antibodies in the mammal by inhibiting the activity of a fibroblast growth factor, such as FGF2, in the mammal.
- a fibroblast growth factor such as FGF2
- a further embodiment of the invention provides a method for treating a microbial infection in a mammal, such as a human, that includes: inhibiting the activity of a fibroblast growth factor, such as FGF2 in a mammal in need of treatment for a microbial infection, to an extent effective to increase antibody production in the mammal.
- the inhibiting step may include or consist of administering a fibroblast growth factor antagonist, such as a FGF2 antagonist, to the mammal in an amount effective to increase antibody production in the mammal.
- the method may further include the step of administering an antibiotic or anti-viral agent to the mammal which is active against the microbial infection.
- Another embodiment of the invention provides a method for increasing in vivo antibody production in a mammal, such as a human, that does not have a cancer that includes the step of by inhibiting the activity of a fibroblast growth factor, such as FGF2, in the mammal.
- a mammal such as a human
- FGF2 fibroblast growth factor
- the mammal is a geriatric human.
- a still further embodiment of the invention provides a method for decreasing antibody production, such as pathological antibody production, in a mammal such as a human, in need of such reduction, by administering to the mammal, in an amount effective to decrease antibody production in the mammal, a fibroblast growth factor or agonist thereof, such as FGF2 or an FGF2 agonist, or an agonist of a receptor that binds a fibroblast growth factor such as FGF2, for example FGFR1, FGFR2 and FGFR3.
- FIG. 1 A shows that FGF2 deficient mice respond more strongly to a Type I Thymus Independent Antigen.
- FIG. IB shows the difference in antibody titer of FGF2 deficient animals compared to littermate controls following immunization.
- FIG. 2A shows FGF2 transgenic mice respond more weakly to a Type I Thymus Independent Antigen.
- FIG. 2B shows the quantification of antibody titer of FGF2 transgenic animals compared to littermate controls following immunization.
- FIG. 3 shows that FGF2 deficiency affects germinal centers but not syndecan expression.
- FIG. 4 shows that ectopic expression of FGF2 does not suppress germinal center formation.
- FGF2 mutant mice FGF2 deficient mice produce more antibody to a Type I independent antigen while FGF2 over-expressing mice show suppressed antibody production to the same pathogenic stimulus.
- germinal center formation is compromised in the absence of FGF2.
- changes in both antibody production and germinal center formation are observed in mice lacking a single copy of FGF2, demonstrating that lymphocytes are particularly sensitive to FGF2 gene dosage.
- FGF2 -/- mice were obtained from two academic sources. These mice display relatively benign defects in wound healing, blood pressure regulation and cortical neurogenesis and do not express detectable levels of FGF2 protein (Ortega et al, 1998. Proc Natl Acad Sci USA 95:5672; Zhou et al, 1998, Nature Medicine 4:20). Both sets of knockouts showed increases in antibody production and data in FIGS. 1 and 3 are for animals obtained from the University of Cincinnati. Heterozygous animals (mixture of 129SvEv:Black Swiss) were mated and heterozygous and null animals were compared to littermate controls. Adult mice of both sexes were used.
- FGF2 transgenic animals exhibit bone dysplasia and disruption of endothelial homeostasis (Fulgham et al, 1999, Endothelium 6: 185; Coffin et al, 1995, Mol Biol Cell 6: 1861).
- Animals (FVBN) heterozygous for the transgene were mated to wild type and adult animals of both sexes were compared to littermate controls. Animals were maintained in a pathogen-free facility, following institutional standards. Protocols adhered to IACUC guidelines.
- mice were immunized intraperitoneally with 50 ug TNP-LPS (tri-nitrophenol lipopolysachharide) emulsified with complete Freund's adjuvant in PBS (200 ul final volume). Serum was harvested from retro-orbital eye bleeds. After coagulation, bleeds were centrifuged and sodium azide (0.01%) was added. ELISAs for TNP specific antisera were performed on plates coated with TNP-BSA (Biosearch) and primary antisera were bound overnight at 4°C. Goat anti-mouse IgG (all Ig isotypes) coupled to Alkaline Phosphatase was used as secondary antisera (Jackson).
- TNP-LPS tri-nitrophenol lipopolysachharide
- Germinal center number was scored by experimenters blind to the source of the sections. At least three serial sections were scored for each spleen. Results are based on three independent experiments from two or more animals per genotype. Data are presented from the final experiment which used the largest number of animals.
- CD43 negative selection was carried out using anti-CD43 (Serotec) and Miltenyi microbeads according to the manufacturer's instructions.
- Cells were cultured in RPMI 1640, 10% fetal calf serum for three days in the presence of anti- CD40 (mAb 1C10, generous gift of Hsiou-Chi Liou, Weill Medical College of Cornell University) and anti-IgM Fab '2 fragments (Jackson Immunoresearch).
- FGFl lOOng/ml
- Heparin lOug/ml
- FGF2 Regulates the Humoral Immune Response
- TNP-LPS type I independent antigen
- FIG. 1 A data points represent average absorbance from the serum of at least five animals. Asterisks indicate statistical differences at p ⁇ .05 (student's t test).
- FIG. IB shows the quantification of the difference in antibody titer of FGF2 deficient animals compared to littermate controls at day nineteen after immunization. Data points represent the mean absorbance +/- s.e.m. at the indicated dilutions for each genotype. Broken line between curves with corresponding vertical line delineates difference in antibody titer at the same absorbance.
- FGF2 transgenic mice To determine whether FGF2 is sufficient to regulate antibody production, we examined the humoral immune response in FGF2 transgenic mice. These animals express a human FGF2 gene driven by the ubiquitously active promoter,
- FGF2 protein phosphoglycerate kinase (Coffin et al., 1995, Mol Biol Cell 6: 1861). Different forms of FGF2 protein are produced from the FGF2 gene, including several high and low molecular weight isoforms. In FGF2 transgenic animals, there is a marked increase in the expression of the 18-Kd form of FGF2 in selected tissues, including spleen (Coffin et al, 1995, Mol Biol Cell 6: 1861).
- FIG. 2B shows the quantification of antibody titer of FGF2 transgenic animals compared to littermate controls at day twenty one after immunization. Data points represent the mean absorbance +/- s.e.m. at the indicated dilutions. Broken line between curves with corresponding vertical line delineates difference in antibody titer at the same absorbance.
- FIG. 1 FGF2 deficiency affects germinal centers but not syndecan expression.
- FGF2 +/+, +/-, -/- mice were immunized i.p. with 50 ug TNP-LPS.
- A-C Spleens were stained for expression of germinal centers with peanut agglutinin two weeks after immunization.
- D-F Expression of syndecan-1 was determined by monoclonal antibody anti-CD 138 (BD).
- FGF2 is one of the more widely expressed members of the FGF family of ligands, with strong expression in multiple tissues.
- functional studies have demonstrated that both FGF-1 and FGF2 are present in the spleen in forms which can stimulate liver cell proliferation (Suzuki et al., 1992, Biochem Biophys Res Commun 186: 1192).
- FGF-1 constitutes a plausible candidate because it structurally resembles FGF2 and also is expressed in the spleen (Suzuki et al, 1992, Biochem Biophys Res Commun 186: 1192).
- studies with FGF- 1/2 double knock out mice suggest that the mild wound healing and neural phenotypes in FGF2 null mice are not a result of FGF-1 substituting for FGF2 (Miller et al, 2000, Mol Cell Biol 20:2260).
- the type I independent antigen lipopolysaccharide is a key pathogenic substance in the cell wall of gram negative bacteria.
- the repeating epitope in this molecule leads to massive engagement of receptors on the surface of B cells, including the BCR, TLR2 and TLR4 (Yang et al, 1998, Nature 395:284; Takeuchi et al, 1999, Immunity 11 :443).
- B cell evolution has developed rapid and vigorous pre-existing defenses against such frequent threats and consequently, antibody secretion in response to this stimulus is robust.
- the greater response in the absence of FGF2 demonstrates that FGF2 negatively regulates the primary humoral immune response.
- FC DRIIB FC DRIIB
- FGF2 may regulate a step subsequent to the expression of syndecan- 1, such as plasmablast migration, full terminal differentiation, or metabolic function of antibody secreting cells in the bone marrow. Consistent with this latter idea, FGF2 is strongly expressed by multiple cell types in the bone marrow (Brunner et al, 1993, Blood 81 :631; Chou et al, 2003, Leuk Res 27:499.).
- FGF2 may control antibody production either by directly signaling to B cells or indirectly by affecting cells which regulate plasma cell activity.
- the direct model is consistent with our data showing decreased proliferation in response to FGF signaling of primary mature B lymphocytes (Table 3). While the reduction in cell number is modest, it should be borne in mind that few substances can overcome the strong growth and survival signals turned on by simultaneous CD40 and BCR engagement. In agreement with a direct mode of action, a previous study reported that FGF receptors exist on normal human peripheral blood B cells (Genot, et al., 1989, Cell Immunol 122:424). However, the possibility that other cell types could mediate the observed effects cannot presently be excluded.
- TNF receptor null animals lack germinal centers but produce substantial antibody titers in response to vesicular stomatitis virus (Karrer et al., 2000, J Immunol 164:768). Similarly, TNF-a null animals display dramatic alterations in splenic morphology but their antibody production to LPS is unaffected (Pasparakis et al, 1996, J Exp Med 184: 1397).
- FGF2 plays two distinct and complementary roles in the humoral immune response. FGF2 facilitates germinal center formation, thereby contributing to the generation of activated B cells which defend against pathogenic stimuli. On the other hand, FGF2 reduces plasma cell activity and in so doing provides a limit on antibody production. Since FGF2 exerts opposing forces at different times during the B cell response, its activities in the immune system are certainly complex. Such complexity is consistent with observations in other tissues, where FGF signaling can stimulate radically different effects depending on its temporal and spatial locus of action.
- Influenza vaccine (Nguyen ML et al Infect Immun. 2009 Nov;77(l l):4714-23.
- the major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross- reactive epitopes);
- Influenza Vaccine in geriatric patients (Frasca D, Diaz, A, Romero, M et al. Vaccine. 2010 Oct 22. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans.); and Anthrax vaccine (Nguyen ML et al Infect Immun. 2009 Nov;77(l l):4714-23.
- the major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.).
- the invention may, for example, be used to increase antibody production and/or humoral immunity in patients, such as human patients, suffering from
- immunodeficiencies including but not limited to: Common variable immunodeficiency (Rezaei N et al Clin Vaccine Immunol. 2008 Apr; 15 (4): 607- 11 Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency); primary immunodeficiency disorder (PIDD), Ig deficiency, IgG deficiency; and HIV disease (Acquired Immune Deficiency Syndrome).
- Common variable immunodeficiency Rezaei N et al Clin Vaccine Immunol. 2008 Apr; 15 (4): 607- 11 Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency
- PIDD primary immunodeficiency disorder
- Ig deficiency IgG deficiency
- HIV disease Acquired Immune Deficiency Syndrome
- One embodiment of the invention provides a method for increasing the humoral immune response to vaccination with an immunogen, for example, an antigen or a live vaccine, in a mammal, that includes: in conjunction with the vaccination of a mammal to the immunogen other than FGF2, inhibiting the activity of FGF2 in the mammal, thereby increasing the humoral immune response to the antigen.
- an immunogen for example, an antigen or a live vaccine
- the immunogen is other than a fibroblast growth factor and other than a fibroblast growth factor receptor.
- the mammal may be a human, such as a geriatric human.
- the mammal which may be human, may have an immune deficiency, such as but not limited to Common variable immunodeficiency; primary immunodeficiency disorder (PIDD), an immunoglobulin deficiency such as IgG deficiency, and HIV disease.
- an immune deficiency such as but not limited to Common variable immunodeficiency; primary immunodeficiency disorder (PIDD), an immunoglobulin deficiency such as IgG deficiency, and HIV disease.
- PIDD primary immunodeficiency disorder
- IgG deficiency immunoglobulin deficiency
- HIV disease HIV disease.
- Another embodiment of the invention provides a method for treating an immune deficiency in a mammal, such as a human, that includes: increasing the production of endogenous antibodies in the mammal by inhibiting the activity of FGF2 in the mammal.
- the mammal does not have cancer.
- the immune deficiency may be, for example, but is not limited to: Common variable
- immunodeficiency primary immunodeficiency disorder (PIDD), an immunoglobulin deficiency such as IgG deficiency, and HIV disease.
- PIDD primary immunodeficiency disorder
- immunoglobulin deficiency such as IgG deficiency
- HIV disease HIV disease.
- Non-human mammals also suffer from immunodeficiencies and may be treated according to the invention.
- the method may be used to treat immunodeficiency associated with feline
- immunodeficiency virus in a cat, such as a domesticated cat.
- a further embodiment of the invention provides a method for treating a microbial infection in a mammal, such as a human, that includes: administering an FGF2 antagonist to a mammal in need of treatment for a microbial infection, wherein the FGF2 antagonist is administered in an amount effective to increase antibody production in the mammal.
- the method may further include the step of: administering an antibiotic or anti-viral agent to the mammal which is active against the microbial infection.
- the antibiotic or anti-viral agent is administered such that the effect of the antibiotic or antiviral agent and that of the FGF2 antagonist are temporally overlapping in the mammal.
- the microbial infection may, for example, be a bacterial infection, a viral infection or a eukaryotic parasite infection.
- the method may further include the step of determining that the mammal has a microbial infection prior to administering the FGF2 antagonist.
- Another embodiment of the invention provides a method for increasing in vivo antibody production in a mammal, such as a human, that does not have a cancer, which includes the step of inhibiting the activity of FGF2 in the mammal.
- the mammal is a geriatric human or non-human mammal, such as a geriatric domesticated dog or cat.
- a related embodiment provides a method for enhancing the production of antisera or polyclonal antibodies generally against a desired immunogen in a non-human mammal that includes the steps of: inhibiting FGF2 activity in the non-human mammal according to any of methods and ways described herein and immunizing the non-human mammal with an immunogen that is not a fibroblast growth factor or a fibroblast growth factor receptor, whereby the production of antibodies against the immunogen in the mammal is enhanced, increased and/or accelerated versus a comparable immunization without the inhibition of FGF2 activity.
- the method may further include the step of retrieving the polyclonal sera from the non-human mammal and optionally the step of isolating.
- the immunizing step may, for example, include more than one temporally separated immunization with the immunogen and may, for example, be aided by inclusion of an immunization adjuvant.
- the methods for production of antisera and polyclonal antibodies are well known and long-established in the art. See, for example, U.S. Pat. No. 5,440,021.
- the increase in antibody production in response to inhibition of FGF2 activity in a mammal is a general characteristic of the invention which is not limited to the type of FGF2 inhibitor that is administered to the mammal to inhibit the activity of FGF2.
- Preferred types of inhibitors of FGF2 activity include antibodies and binding fragments thereof, both monoclonal and polyclonal, which bind to FGF2 and block its interaction with FGF binding receptors and antibodies, both monoclonal and polyclonal, which bind to an FGF receptor such as FGFR1, FGFR2 and FGFR3 and block binding of the ligand (FGF2) to the receptor.
- FGF2 ligand
- a single chain, monoclonal scFv antibody that neutralizes FGF2 may be used such as that described in Tao et al, Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2, Biochem Biophys Res Commun. 2010 Apr 9;394(3):767-73.
- Antibodies contain one or more antigen binding sites that specifically binds with an antigen.
- Antibodies include, but are not limited to polyclonal, monoclonal, chimeric, and humanized antibodies.
- Immunologically active portions include
- Immunologically active portions can be incorporated into multivalent from such as diabodies, triabodies, and the like.
- Antibodies further include antigen binding fragments displayed on phage, and antibody conjugates.
- an "isolated antibody” is an antibody that (1) has been partially, substantially, or fully purified from a mixture of components; (2) has been identified and separated and/or recovered from a component of its natural environment; (3) is monoclonal; (4) is free of other proteins from the same species; (5) is expressed by a cell from a different species; or (6) does not occur in nature. Isolated antibodies may, for example, be used as inhibitors of FGF2 activity according to the invention.
- isolated antibodies include an anti-FGF2 antibody that has been affinity purified using FGF2, an anti-FGF2 antibody that has been made by a hybridoma or other cell line in vitro, a human anti- FGF2 antibody isolated from a library such as a phage library, and a human anti-FGF2 antibody derived from a transgenic mouse.
- Naturally occurring antibody molecules are composed of two identical heavy chains and two light chains.
- Each light chain is usually covalently linked to a heavy chain by an interchain disulfide bond, and the two heavy chains are further linked to one another by multiple disulfide bonds at the hinge region.
- the individual chains fold into domains having similar sizes (about 110-125 amino acids) and structures, but different functions.
- the light chain comprises one variable domain (V L ) and one constant domain (C L ).
- the heavy chain comprises one variable domain (V H ) and, depending on the class or isotype of antibody, three or four constant domains (C H I , C H 2, C H 3 and C H 4).
- the isotypes are IgA, IgD, IgE, IgG, and IgM, with IgA and IgG further subdivided into subclasses or subtypes.
- the portion of an antibody consisting of V L and V H domains is designated "Fv” and constitutes the antigen-binding site.
- a single chain Fv (scFv) is an engineered protein containing a V L domain and a V H domain on one polypeptide chain, wherein the N terminus of one domain and the C terminus of the other domain are joined by a flexible linker.
- Fab refers to the portion of the antibody consisting of V L -C L (i.e., a light chain) and V H -C H 1 (also designated "Fd").
- Antibodies include without limitation single variable domains (sVDs) and antigen binding proteins that comprise sVDs.
- sVD binding sites can be obtained from antigen specific Fv regions (which comprise both V H and V L domains). Often, it can be shown that the binding affinity and specificity of an Fv region is contributed primarily by one of the variable domains. Alternatively, the scFv can be obtained directly.
- Direct sources of sVDs include mammals (e.g., camelids) that naturally express antibodies containing only V H domain.
- phage display libraries can be constructed to express only a single variable domain. For example, a human domain antibody phage display library is commercially available from Domantis (Cambridge, UK).
- the antibody variable domains show considerable amino acid sequence variablity from one antibody to the next, particularly at the location of the antigen binding site.
- Three regions, called “complementarity-determining regions” (CDRs) are found in each of V L and V H -
- the CDRs of an antibody are often referred to as
- Fc is the designation for the portion of an antibody which comprises paired heavy chain constant domains.
- the Fc comprises C H 2 and C H 3 domains.
- the Fc of an IgA or an IgM antibody further comprises a C H domain.
- the Fc is associated with Fc receptor binding, activation of complement-mediated cytotoxicity and antibody-dependent cellular-cytotoxicity.
- complex formation requires Fc constant domains.
- antibodies of the invention include, but are not limited to, naturally occurring antibodies, bivalent fragments such as (Fab') 2 , monovalent fragments such as Fab, single chain antibodies, single chain Fv (scFv), single domain antibodies, multivalent single chain antibodies, diabodies, triabodies, and the like that bind specifically with antigens.
- Antibody fragments also include polypeptides with amino acid sequences substantially similar to the amino acid sequence of the variable or hypervariable regions of the antibodies of the invention. Substantially the same amino acid sequence is defined herein as a sequence with at least 70%, at least about 80%, at least about 90%>, at least about 95% or at least about 99% homology or identity to a compared amino acid sequence, as determined by the FASTA search method in accordance with Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988).
- Antibodies that may be employed as inhibitors according to the invention also include "chimeric" antibodies and binding fragments thereof. Such antibodies generally comprise variable domains of one antibody and constant domains of a different antibody. Typically, to minimize host immune responses against the antibody and to enhance host responses against the antibody target by retaining antibody effector functions, the constant domains of a chimeric antibody are taken from the same species to which the chimeric antibody will be administered.
- Antibodies that may be employed as inhibitors according to the invention also include "humanized" antibodies.
- Humanized variable domains are constructed in which amino acid sequences which comprise one or more complementarity determining regions (CDRs) of non-human origin are grafted to human framework regions (FRs).
- CDRs complementarity determining regions
- FRs human framework regions
- Variable domains have a high degree of structural homology, allowing easy identification of amino acid residues within variable domains which corresponding to CDRs and FRs. See, e.g., Kabat, E. A., et al, 1991 , Sequences of Proteins of Immunological Interest. 5th ed. National Center for Biotechnology
- CDRs are most easily grafted onto different FRs by first amplifying individual FR sequences using overlapping primers which include desired CDR sequences, and joining the resulting gene segments in subsequent amplification reactions. Grafting of a CDR onto a different variable domain can further involve the substitution of amino acid residues which are adjacent to the CDR in the amino acid sequence or packed against the CDR in the folded variable domain structure which affect the conformation of the CDR.
- Humanized variable domains of the invention therefore include human domains which comprise one or more non-human CDRs as well as such domains in which additional substitutions or replacements have been made to preserve or enhance binding characteristics.
- Antibodies with variable domains that have been made less immunogenic by replacing surface-exposed residues so as to make the antibody appear as self to the immune system may also be employed as inhibitors (Padlan, E. A., 1991, Mol. Immunol. 28, 489-98). Antibodies have been modified by this process with no loss of affinity (Roguska et al, 1994, Proc. Natl. Acad. Sci. USA 91, 969-973). Because the internal packing of amino acid residues in the vicinity of the antigen binding site remains unchanged, affinity is preserved. Substitution of surface-exposed residues according to the invention for the purpose of reduced immunogenicity does not mean substitution of CDR residues or adjacent residues which influence binding characteristics.
- variable domains that are essentially human as when the recipient of the antibody is human.
- Human antibodies comprise human VH and VL framework regions (FWs) as well as human complementary determining regions (CDRs).
- FWs human VH and VL framework regions
- CDRs human complementary determining regions
- the entire VH and VL variable domains are human or derived from human sequences.
- the antibodies can be obtained directly from human cells, for example by creating human hybridomas.
- human antibodies can be obtained from transgenic animals into which unrearranged human Ig gene segments have been introduced and in which the endogenous mouse Ig genes have been inactivated (reviewed in Briiggemann and Taussig, 1997, Curr. Opin. Biotechnol. 8, 455-58).
- Preferred transgenic animals contain very large contiguous Ig gene fragments that are over 1 Mb in size (Mendez et al., 1997, Nature Genet. 15, 146-56) but human Mabs of moderate affinity can be raised from transgenic animals containing smaller gene loci (See, e.g., Wagner et al, 1994, Eur. J. Immunol. 42, 2672-81; Green et al, 1994, Nature Genet. 7, 13-21).
- Human antibodies can also be obtained from libraries of antibody VH and/or VL domains.
- a variable domain library can be obtained from human genomic sequences, or from peripheral blood lymphocyte expressing productively rearranged variable region genes.
- the human gene library can be synthetic.
- variable domain libraries can be created which comprise human framework regions with one or more CDRs that are synthesized to include random or partial random sequences.
- a human VH variable domain library can be created in which members are encoded by a human VH gene segment and a synthetic sequence for the CDR3H region (i.e., a synthetic D H -JH gene segment).
- a human VL variable domain may be encoded by a human VL gene segment and a synthetic sequence for the CDR3L region (i.e., a synthetic J L gene segment).
- the human frameworks may be synthetic in that they have a consensus sequence derived from known human antibody sequences or subgroups of human sequences.
- one or more CDRs is obtained by amplification from human lymphocytes expressing rearranged variable domains and then recombined into a particular human framework.
- variable domains In order to screen libraries of variable domains, it is common to employ phage display libraries wherein combinations of human heavy and light chain variable domains are displayed on the surface of filamentous phage (see, e.g., McCafferty et al, 1990, Nature 348, 552-54; Aujame et al, 1997, Human Antibodies 8, 155-68). Combinations of variable domains are typically displayed on filamentous phage in the form of Fabs or scFvs. The library is screened for phage bearing combinations of variable domains having desired antigen binding characteristics. Preferred single domain and variable domain combinations display high affinity for a selected antigen and little cross-reactivity to other related antigens.
- binding domains of the invention include those for which binding characteristics have been improved by mutating CDRs and/or FW regions by direct mutation, methods of affinity maturation, or chain shuffling. It is understood that amino acid residues that are primary determinants of binding of single domain antibodies can be within Kabat defined CDRs, but may include other residues as well.
- residues important for antigen binding can also potentially include amino acids that would otherwise be located at the interface of a V H -V L heterodimer.
- phage display is used to screen such mutants to identify those having the desired binding characteristics (see, e.g., Yang et al, J. Mol. Biol, 254: 392-403 (1995)). Mutations can be made in a variety of ways. One way is to randomize individual residues or
- mutations may be induced over a range of CDR residues by error prone PCR methods (see, e.g., Hawkins et al, J. Mol. Biol, 226: 889-896 (1992)).
- phage display vectors containing heavy and light chain variable region genes may be propagated in mutator strains of E. coli (see, e.g., Low et al, J. Mol. Biol, 250: 359-368 (1996)).
- Inhibitors that may be used according to the invention also include antigen binding proteins engineered from non-immunoglobulin scaffolds.
- affibodies which are derived from an immuno globulin-binding domain of S. aureus protein A, possess no disulfide bonds and display reversible folding.
- fibronectin which has an antibody-like structure and displays CDR-like loops. In contrast to antibodies, the fibronectin domain structure does not rely on disulfide bonds, yet displays high thermodynamic stability. Binding sites can be engineered into such scaffolds by, for example, diversifying codons at specified positions and screening for binding to a desired antigen.
- Codons can be randomized in loops, flat surfaces, cavities, or combinations of such locations. Further, peptide sequences can be inserted, usually in loops. Target-binding variants of resulting libraries can be isolated using selection of screening techniques that are well known in the art, not limited to phage display, ribosome display, bacteria or yeast surface display, and the like. For antigen-binding proteins intended for therapy, various strategies are available for minimizing potential immunogenicity. Human scaffolds can be employed, and immunogenicity can be minimized, for example, by PEGylation or T-cell epitope engineering (i.e., minimizing T- cell reactive sequences).
- Antigen-binding proteins from non-immunoglobulin scaffolds often can be produced more economically than immunoglobulin-type proteins.
- the absence of disulfide bonds or free cysteines allows for expression of functional molecules in the reducing environment of the bacterial cytoplasm, which usually gives higher yields than periplasmic expression, and is more convenient than refolding in vitro.
- Binz, H. K. et al. discloses a variety of such antigen-specific binding proteins and techniques for their development.
- the identification or selection of antibodies or other molecules that inhibit binding of FGF2 or other FGFs to their receptors may be performed according to routine ligand-receptor binding assays, comparing binding in presence and absence of test agent, since the full sequences of FGF2 and its receptors are known in various mammals such as human. See, for example, U.S. Pat. No. 5,440,021 for ligand-receptor binding assays.
- Another preferred type of inhibitor of FGF2 activity is a soluble FGF2- binding receptor or soluble portion of an FGF-binding receptor, such as a soluble form of FGFRl, FGFR2 and FGFR3.
- the soluble receptor sequence may, for example match the species in which it will be administered, i.e., a human receptor sequence may be used for a human recipient and so on.
- FP-1039 is a soluble fusion protein consisting of the extracellular domains of human FGFRl linked to the Fc region of human
- Immunoglobulin Gl (IgGl), which may be used as an FGF2 inhibitor/antagonist according to the invention (Five Prime Therapeutics, Inc., San Francisco, CA; Keer et al, ASCO 2010, Abstract no. TPS260).
- FGF2 activity may also be inhibited according to the invention by vaccinating the subject mammal against FGF2 itself or against FGFRl, FGFR2 and/or FGFR3.
- a peptide vaccine targeting the heparin-binding portion of FGF2 can be used to generate a specific anti-FGF2 antibody response in a mammal according the method of Plum et. al., Generation of a specific immunological response to FGF2 does not affect wound healing or reproduction, Immunopharmacol Immunotoxicol. 2004 Feb;26(l):29- 41.
- a composition for intravenous administration for example, to a human, may include 0.1 to 20 mg, such as 0.1 to 10 mg, of the polypeptide, and this may be a daily dose. More generally, dosages from 0.1 mg to about 100 mg per subject per day for one or more days may be used.
- Methods for preparing administrable compositions are well known to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, Pa. (1995).
- Polypeptides for administration to a subject may, for example, be provided in lyophilized form and rehydrated with sterile water before administration.
- the solution of polypeptide may then be added to an infusion bag containing 0.9% sodium chloride, USP, and, for example administered at a dosage of from 0.5 to 15 mg/kg body weight.
- the polypeptide can be administered as a bolus injection, for example, at a dosage of 0.5 to 30 mg/kg body weight.
- FGF2 activity inhibitors include, for example, antisense oligonucleotides targeting FGF2 or one or more of FGFR1, FGFR2 and
- FGFR3 FGFR3.
- Still further suitable inhibitors are small molecule inhibitors, for example cardiac glycosides or aglycone derivatives as described in U.S. Pat. No. 6,071,885 and
- TKI258 also known as CHIR-258 described in Sarker et al., Clin Cancer Res,
- the invention also provides embodiments in which antibody production in vivo is purposefully reduced in a mammal, such as a human, by increasing FGF2 activity in the mammal, for example, by administration of FGF2 to the mammal or administration of an agonist of FGF2 or an agonist of an FGF2 receptor, such as FGFR1, FGFR2 or
- the peptide sequence may, for example at least substantially or identically match the species in which it will be administered, i.e., a human receptor sequence may be used for a human recipient and so on.
- This aspect of the invention finds practical application is the suppression of antibody production in acutely toxic states.
- response to invading pathogens can lead to pathological autoimmune effects, with lymphocyte activity spiraling out of control.
- administration of FGF2 attenuates the uncontrolled secretion of antibody.
- autoimmune antibodies are observed in both systemic lupus erythematosus (Cohen D et al., Diagnosis and management of the antiphospho lipid syndrome. BMJ. 2010 May 14;340:c2541) and diverse arthritic disease (Calero I, et al., B cell therapies for rheumatoid arthritis: beyond B cell depletion. Rheum Dis Clin North Am 2010
- rheumatoid arthritis including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
- increasing FGF2 activity in a mammal may be used to decrease or maintain a decreased level of antibody production in organ transplant patients, such as human organ transplant patients in order to decrease negative immune responses to and increase tolerance to the transplanted organ in the patient.
- one embodiment of the invention provides a method for decreasing antibody production, such as pathological antibody production, in a mammal such as a human in need thereof by administering to the mammal FGF2 or an FGF2 agonist or an agonist of a receptor that binds FGF2 such as FGFR1, FGFR2 and FGFR3 in an amount effect to decrease antibody production in the mammal.
- the mammal may have and be in need of treatment for systemic lupus erythematosus and diverse arthritic disease, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis and the method decreases the production of autoimmune antibodies in these mammals thereby treating the condition.
- the mammal is an organ transplant patient such as a human organ transplant patient and the method reduces antibody response against the transplanted organ.
- fibroblast growth factors and their receptors are well characterized in humans and non-human mammals.
- the following sequences are known and form part of this disclosure: Human FGF2 (NCBI Reference Sequence NM 002006.4; SEQ ID NO: l peptide, SEQ ID NO:2 nucleotide), Human FGFR1 (GenBank Accession No. M34185.1; SEQ ID NO:3 peptide, SEQ ID NO:4 nucleotide), Human FGFR2 (NCBI Reference Sequence NM 000141.4; SEQ ID NO:5 peptide, SEQ ID NO:6 nucleotide), Human FGFR3 (NCBI Reference Sequence
- the invention also provides methods for increasing endogenous antibody production in mammals such as humans by administering any of the following enumerated compounds or pharmacologically acceptable salts thereof: [000105] 1. BIBF1120 (Vargatef) Boehringer Ingelheim,
- BIBF 1120 triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
- AZD2171 a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
- AZD4547 an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
- TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti- angio genesis.
- ENMD-2076 an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
- FP1039 (fusion protein) Five Prime, Human Genome Sciences, Glaxo Smith Kline.
- FP 1039 comprises the extracellular domain of human fibroblast growth factor receptor lc (FGFR1) linked to the Fc portion of human IgGl .
- the molecule is designed to trap FGFR1 ligands and prevent binding to FGF receptors.
- Harding et al Preclinical efficacy of FP- 1039 (FGFR1 :Fc) in endometrial carcinoma models with activating mutations in FGFR2. 101st Annual Meeting of the American Association for Cancer Research. : abstr. 2597, 17 Apr 2010
- the compounds or pharmacologically acceptable sales thereof may, for example, be administered in therapeutically effective amounts to a mammal such as a human in need of increasing endogenous antibody production who is not in need of treatment for a cancer.
- the mammal may have an immune deficiency such as a humoral immune deficiency or any of the immune deficiencies described herein.
- the mammal may, for example, be geriatric.
- the compounds or pharmaceutically acceptable salts thereof may for example, be administered in an amount effective to increase endogenous antibody production in conjunction with a vaccination with an immunogen (other than FGF2 or an FGF) to improve the humoral immune response to the vaccination.
- the compounds or pharmaceutically acceptable salts thereof may for example, be
- the mammal may be one that is not in need of treatment for cancer.
- the invention also provides corresponding first and second medical uses for each of the methods of treatment described in this disclosure.
- the invention provides the use of the agents for treatment of the conditions described and also provides use of the agents for the manufacture of medicaments for the treatment of the conditions described.
- Non-human mammals with which the invention may be used include, for example, livestock animals, such as Bovidae, for example cows and sheep, and swine, also Equidae such as horses, canines such as companion domesticated dogs and felines such as companion domesticated cats, primates, Lagomorphs such as rabbits and
- Rodentia such as rats and mice.
- the invention is also applicable in birds such as foul, for example, chickens, turkeys and quail, ducks and geese. Accordingly, the invention provides corresponding embodiments and variations as described herein for mammals but applied to avians, such as the aforementioned avians.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/039758 WO2014182277A1 (en) | 2013-05-06 | 2013-05-06 | Fgf modulation of in vivo antibody production and humoral immunity |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2994130A1 true EP2994130A1 (en) | 2016-03-16 |
EP2994130A4 EP2994130A4 (en) | 2017-02-22 |
Family
ID=51867595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13884155.6A Withdrawn EP2994130A4 (en) | 2013-05-06 | 2013-05-06 | Fgf modulation of in vivo antibody production and humoral immunity |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2994130A4 (en) |
JP (1) | JP2016520060A (en) |
WO (1) | WO2014182277A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2896247B1 (en) * | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF |
-
2013
- 2013-05-06 JP JP2016512884A patent/JP2016520060A/en active Pending
- 2013-05-06 WO PCT/US2013/039758 patent/WO2014182277A1/en active Application Filing
- 2013-05-06 EP EP13884155.6A patent/EP2994130A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2014182277A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2016520060A (en) | 2016-07-11 |
WO2014182277A1 (en) | 2014-11-13 |
EP2994130A4 (en) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Latres et al. | Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice | |
JP6649254B2 (en) | Modulokines based on IL-15 and IL-15Rα sushi domains | |
CN108137681A (en) | The variant of the optimization of anti-VEGF antibodies | |
DE60313859T2 (en) | INDUCTION OF ANTI-TUMOR CTL IMMUNITY BY IN VIVO ACTIVATION OF 4-1BB AND / OR CD40 | |
JP2022064935A (en) | Methods for treating gi syndrome and graft versus host disease | |
JP2020510653A (en) | Multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, CEA or claudin-18.2. | |
CN104955838A (en) | Bispecific EGFR/c-Met antibodies | |
KR20170080604A (en) | Anti-interleukin-33 antibodies and uses thereof | |
Lei et al. | Growth factors outside the PDGF family drive experimental PVR | |
ES2774422T3 (en) | Antibodies to IL-21 | |
JP2020521448A (en) | Proteins that bind to NKG2D, CD16, and ROR1 or ROR2 | |
EA025245B1 (en) | Anti-cd100 antibodies and methods for using the same | |
JP7431394B2 (en) | Multispecific binding proteins that bind HER2, NKG2D and CD16 and methods of use | |
JP2020507328A (en) | Protein binding to BCMA, NKG2D and CD16 | |
JP2020508997A (en) | Proteins that bind to Her2, NKG2D and CD16 | |
CN110279872A (en) | Conjugated body of the cytotoxic molecule with cell bound receptor molecule | |
TW201815417A (en) | Combination use of anti-PD-1 antibody and IDO inhibitor in the preparation of a medicament for the treatment of tumor | |
US20230151081A1 (en) | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets | |
JP2020522474A (en) | Proteins that bind to NKG2D, CD16, and tumor associated antigens | |
JP2023106433A (en) | Proteins binding nkg2d, cd16 and flt3 | |
JP2020510644A (en) | Protein binding to GD2, NKG2D and CD16 | |
JP2020507577A (en) | Protein binding to PSMA, NKG2D and CD16 | |
JP2840131B2 (en) | Method for suppressing humoral immunity persistence | |
JP2017520554A (en) | Methods and pharmaceutical compositions for the treatment of inflammatory bowel disease | |
CN103214555B (en) | Peptide inhibitors for mediating stress responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170119 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 43/00 20060101ALI20170113BHEP Ipc: A61K 31/496 20060101ALI20170113BHEP Ipc: A61K 31/519 20060101ALI20170113BHEP Ipc: A61K 31/365 20060101ALI20170113BHEP Ipc: A61K 31/4709 20060101ALI20170113BHEP Ipc: A61K 31/405 20060101AFI20170113BHEP Ipc: A61K 31/5025 20060101ALI20170113BHEP Ipc: A61K 31/506 20060101ALI20170113BHEP Ipc: A61K 31/513 20060101ALI20170113BHEP Ipc: A61K 31/403 20060101ALI20170113BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170818 |